Background / Aims: Exenatide is a glucagon-like peptide-type 1 (GLP-1) approved for treatment of diabetes. Unlike insulin it has an added advantage of lowering body weight in obese type 2 diabetics. Literature for its therapeutic usefulness in Australian population is scanty and in North Queensland is lacking despite reportedly high prevalence of diabetes, obesity in the region. The aim of the study was to document metabolic effects of exenatide in our local diabetes population.\ud
\ud
Methods: We conducted a retrospective review of 221 patients with type 2 diabetes mellitus treated with exenatide for 24 months at the Townsville Hospital Diabetes Clinic.\ud
\ud
Results: These are the preliminary results. Range (Mean) HbA1c(%) at start 7.3-13 (10.15). Latest HbA1c 6.5-10.8 (8.65). Change in HbA1c +0.7 till -3.5 (-1.4). Weight(Kg) at start 94-184 (139). Change in weight -20 till +2 (-9).\ud
\ud
Conclusion: The preliminary results are favourable with fall in HbA1c by 1.4% and 9 kg weight loss. These results are from a small sample of the total patients and are comparable to the studies published
